Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab

Fig. 1

Association between the change in peripheral blood Treg frequency and Treg suppressive function (change in % Treg proliferation after the treatment) across different Treg:Th ratios. The change (week 6 level – baseline level) in circulating Treg was measured phenotypically as CD4+/CD25hi/Foxp3+ (Diff CD4+CD29hiFoxp3+, left column), CD4+/CD25hi/CD39 (Diff CD4+CD25+CD39+, middle column), or the percent of circulating Treg (Diff %Treg in CD4+ Cells, right column). The percent suppressive activity, calculated as the week 6 % Treg inhibition – baseline % Treg function, at 1:1 (Diff 1:1, top row), 1:2 (Diff 1:2, middle row), or 1:5 (Diff 1:5, bottom row) was plotted against the frequency of Treg across all patients with valid test results. There was no statistically significant association (p values on each part). Fewer than 18 data points were generated due to missing values on some patients

Back to article page